Study confirms that SARS-CoV-2 cannot be transmitted to people by mosquitoes

Study confirms that SARS-CoV-2 cannot be transmitted to people by mosquitoes

A new study by Kansas State University researchers is the first to confirm that SARS-CoV-2 cannot be transmitted to people by mosquitoes. Stephen Higgs, associate vice president for research and director of the university's Biosecurity Research Institute, or BRI, together with colleagues from the BRI and the College of Veterinary Medicine had the findings published July 17 by Scientific Reports . The article, "SARS-CoV-2 failure to infect or replicate in mosquitoes: an extreme challenge," details the study's findings, which provide the first experimental investigation on the capacity of SARS-CoV-2, the virus that causes COVID-19 disease, to infect and be transmitted by mosquitoes. "While the World Health Organization has definitively stated that mosquitoes cannot transmit the virus, our study is the first to provide conclusive data supporting the theory," said Higgs, Peine professor of biosecurity and university distinguished professor of diagnostic medicine and pathobiology. The study, which was done at the BRI, a biosecurity level-3 facility, ultimately found that the virus is unable to replicate in three common and widely distributed species of mosquitoes -- Aedes aegypti, Aedes albopictus and Culex quinquefasciatus -- and therefore cannot be transmitted to humans. I am proud of the work we are doing at K-State to learn as much as we can about this and other dangerous pathogens. This work was possible because of the unique capabilities of the BRI and the dedicated BRI and institutional staff." Stephen Higgs, Director, Biosecurity Research Institute, Kansas State University Related Stories



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More